NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









LinqMed Inc.

LinqMed Inc.

Private
Chiba, TokyoHealthcare & Life Scienceshttps://linqmed.co.jp/

Last Round

Series B

Extension

May 12, 2025

Total Funding Raised

$39.55M

Company Overview

LinqMed Inc. is a radiopharmaceutical company developing a drug discovery platform and innovative 'visible' anti-cancer treatments using the copper radioisotope 64Cu.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Medical Imaging

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts, Data as a Service

AI Layer

Non-AI

Keywords

radiopharmaceuticalstheranosticsradiopharmacancer therapycopper-6464Cu-ATSMtargeted radionuclide therapyradioligand therapyPET imagingoncologyclinical stage biotechradioisotope productionhypoxic tumor targetingdrug discovery platformglioblastoma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LinqMed Inc. Comps

Public and private peers based on sector, stage, and business model.

LinqMed Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

LinqMed Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 12, 2025
Series B ExtensionApr 9, 2025
Series BJan 10, 2025
Series ADec 22, 2023
GrantDec 22, 2023

LinqMed Inc. Investors

Notable investors and investment history

LinqMed Inc. investors
InvestorRounds
Sumitomo Mitsui Trust BankSeries B Extension
Keio Innovation InitiativeSeries B Extension
Mizuho CapitalSeries A
New Energy and Industrial Technology Development OrganizationGrant
Chibagin CapitalSeries B Extension
Bio-Sight CapitalSeries A, Series B Extension
Nissay CapitalSeries B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2025

    $2M round with Nissay Capital participating.

  • Apr 9, 2025

    $14.47M round with Sumitomo Mitsui Trust Bank and Chibagin Capital.

LinqMed Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

LinqMed Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about LinqMed Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersChiba, Tokyo
Year Founded2022
Last FundingMay 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.